Condition
Hypersensitivity, Delayed
Total Trials
3
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 1 (1)
Trial Status
Completed2
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06755281Not ApplicableRecruiting
Risk-stratified Testing for Safe Removal of Penicillin Allergy Labels
NCT04454229Not ApplicableCompleted
The Use of Penicillin Allergy Clinical Decision Rule to Enable Direct Oral Penicillin Challenge
NCT01978483Phase 1Completed
Effect of RANKL Inhibition on UV-induced Immunosuppression
Showing all 3 trials